RFL News and Press, Rafael Holdings Inc. Class B From 05/02/22

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

Rafael Holdings press release (NYSE:RFL): FQ2 GAAP EPS of -$0.12. Revenue of $1.11M (+15.6% Y/Y). For further details see: Rafael Holdings GAAP EPS of -$0.12, revenue of $1.11M

NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and six months ended January 31, 2022. The end of our second fiscal quarter marks a ...

Rafael Holdings (NYSE:RFL) filed for a secondary offering of ~2.8M class B shares by selling stockholders, par value $0.01/share. RFL will not receive any proceeds from this offering, as per an SEC filing. As of Feb. 11, there were ~20.9M class B shares outstanding. For further details...

Rafael Holdings (NYSE:RFL) has terminated a merger agreement with Rafael Pharmaceuticals that was announced in June 2021. Rafael Holdings holds 51% of the outstanding capital stock of the latter, which is a private-owned late-stage oncology company. An SEC filing did not provide a reason...

NEWARK, N.J., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and immune metabolism therapeuties through its Barer Institute and investment in Rafael Pharmaceuticals, Inc. and other early-stage ventures, toda...

CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its Phase 2 c...

CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced the completion of the first cohort of dose escalation with no...

NEWARK, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage cancer and immune metabolism therapeutics company, today reported its financial results for the first quarter of its 2022 fiscal year, the three months ended October 31, 2021. We have made sig...

CRANBURY, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced a publication on its Phase 2 clinical trial of CPI-613 ...